DefinitionThis section has been translated automatically.
Dipyridamole belongs to the group of glycoprotein IIb/IIIa receptor blockers.
Pharmacodynamics (Effect)This section has been translated automatically.
Dipyridamole reduces the release of intrathrombocytic ionized calcium and decreases the calcium influx. In addition, the supply of ADP is reduced, thus inhibiting ADP-mediated platelet aggregation. It also inhibits the uptake of adenosine into the endothelium, platelets and erythrocytes. It also blocks cyclo-GMP and cyclo-AMP phosphodiesterases.
Further effects of dipyridamole are the stimulation of the synthesis and release of prostacyclin and an antagonization of the coagulation-promoting effect of the subendothelial structures, especially via the nitric oxide effect.
You might also be interested in
IndicationThis section has been translated automatically.
Dipyridamole is used in combination with ASA for secondary prevention of TIA or apoplexy.
Dosage and method of useThis section has been translated automatically.
3 x 75 mg p.o.; in combination with ASS: Aggrenox (200 mg + 25 mg). Dosage: 2 x 1 tablet,
PreparationsThis section has been translated automatically.
Curantyl N ®.
LiteratureThis section has been translated automatically.
- HA Neumann (2014) The coagulation system. ABW-Scientific Publisher GmbH Berlin
Prof. Dr. med. Peter Altmeyer